BRCA1 and breast carcinoma: We also confirmed the therapeutic effect of the combination of olaparib and 4OH-TAM in ER+ breast cancer cells, CAMA-1 and ZR75-1 that had WT BRCA1 and were resistant to olaparib (Fig 7B).